Technology Bundle ID
TAB-3335

Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens

Linked ID
E-270-2015-0
Lead Inventors
Barney Graham (NIAID)
Peter Kwong (NIAID)
Co-Inventors
Aliaksandr Druz (NIAID)
Cheng Cheng (NIAID)
Guillaume Stewart-Jones (NIAID)
Ivelin Georgiev (NIAID)
John Mascola (NIAID)
Joseph Van Galen (NIAID)
Masaru Kanekiyo (NIAID)
Michael Joyce (NIAID)
Paul Thomas (NIAID)
Rita Chen (NIAID)
Ulrich Baxa (NIAID)
Yaroslav Tsybovsky (Leidos Biomedical Research, Inc)
Yongping Yang (NIAID)
ICs
NIAID
Antigens on the surface of virus particles are displayed in a regular, repetitive pattern which facilitates B cell activation. Presenting trimeric antigens on engineered particles that mimic the geometric patterns observed for native viral proteins can lead to an improved host antibody response.

Self-assembling globular ferritin nanoparticles have previously been used to display multiple copies of a co-assembled trimeric antigen to the immune system. However, prior ferritin nanoparticle technologies only permit a random co-assembly of diverse trimeric antigens, and therefore cannot guarantee the pattern and ratio of diverse trimeric antigens on a single ferritin nanoparticle.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases are developing novel recombinant ferritin nanoparticles that are based on insect ferritin proteins, and that have been engineered to display two different trimeric antigens in a defined ratio and geometric pattern. This system has been tested with antigens derived from HIV-1 envelope (Env) and influenza hemagglutinin (HA). Interestingly, when guinea pigs are immunized with ferritin nanoparticles displaying two different trimeric antigens, induced B cells could simultaneously recognize both trimeric antigens, thus leading to an immune response with improved neutralization breadth.

This technology can be used as a platform for multimerized display of trimeric antigens such as viral type I fusion glycoproteins, and may be applied to many high-priority vaccine targets, such as HIV-1, influenza, respiratory syncytial virus, parainfluenza viruses, and coronaviruses.
Commercial Applications
  • Platform for multimerized immunogen presentation and vaccine design.
  • Vaccines for pathogens that use genetic diversity to escape the immune response.
Competitive Advantages
  • Particles have equal fractions of two different antigens in a specific configuration on the nanoparticle surface (unlike regular ferritin used previously)
  • Designed particles have a geometry that allows for attachment of trimeric antigens (unlike the native insect ferritin).

Request More Info

Licensing Contact: